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Abstract
Background and Objectives:While animal studies have implicated derangements
of global energy homeostasis in the pathogenesis of acute alcoholic hepatitis
(AAH), the relevance of these findings to the development of human AAH remains
unclear. Using global, unbiased serum metabolomics analysis, we sought to
characterize alterations in metabolic pathways associated with severe AAH and
identify potential biomarkers for disease prognosis.
Methods: This prospective, case-control study design included 25 patients with
severe AAH and 25 ambulatory patients with alcoholic cirrhosis. Serum samples
were collected within 24 hours of the index clinical encounter. Global, unbiased
metabolomics profiling was performed. Patients were followed for 180 days after
enrollment to determine survival.
Results: Levels of 234 biochemicals were altered in subjects with severe AAH.
Random-forest analysis, principal component analysis, and integrated hierarchical
clustering methods demonstrated that metabolomics profiles separated the two
cohorts with 100% accuracy. Severe AAH was associated with enhanced
triglyceride lipolysis, impaired mitochondrial fatty acid beta oxidation, and
upregulated omega oxidation. Low levels of multiple lysolipids and related
metabolites suggested decreased plasma membrane remodeling in severe AAH.
While most measured bile acids were increased in severe AAH, low deoxycholate
and glycodeoxycholate levels indicated intestinal dysbiosis. Several changes in
substrate utilization for energy homeostasis were identified in severe AAH,
including increased glucose consumption by the pentose phosphate pathway,
altered tricarboxylic acid (TCA) cycle activity, and enhanced peptide catabolism.
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Finally, altered levels of small molecules related to glutathione metabolism and
antioxidant vitamin depletion were observed in patients with severe AAH.
Univariable logistic regression revealed 15 metabolites associated with 180-day
survival in severe AAH.
Conclusion: Severe AAH is characterized by a distinct metabolic phenotype
spanning multiple pathways. Metabolomics profiling revealed a panel of biomarkers
for disease prognosis, and future studies are planned to validate these findings in
larger cohorts of patients with severe AAH.
Introduction
Acute alcoholic hepatitis (AAH) is a systemic condition that affects 10–35% of
individuals with chronic ethanol use [1, 2]. AAH is characterized by the rapid
development of jaundice, hepatomegaly, and features of the systemic inflamma-
tory response syndrome (SIRS). Maddrey’s Discriminant Function (mDF) is the
most commonly used scoring system to assess severity of AAH [3, 4], and an mDF
.32 with or without hepatic encephalopathy is associated with up to 39% six-
month mortality [5].
Macrovesicular steatosis, or intrahepatic lipid accumulation, is a key histologic
feature of AAH [6]. Early studies of ethanol-fed rodents have suggested that
steatosis may be due to alterations in hepatic lipid metabolism, including
enhanced de novo lipogenesis, reduced hepatic very low density lipoprotein
(VLDL) secretion, and altered fatty acid oxidation (FAO) [7–11]. More recent
work, however, has implicated extrahepatic derangements in global energy
homeostasis such as dysregulated adipose tissue triglyceride hydrolysis and altered
substrate utilization [12].
While animal models have yielded valuable insights into the pathogenesis of
alcoholic steatosis, the relevance of these findings to the development of human
alcoholic hepatitis remain less clear. Therefore, the aim of our study was to
describe systemic metabolic phenotypes in acute alcoholic hepatitis. We
performed an unbiased serum metabolomics analysis in a prospectively-collected
cohort of patients hospitalized with severe AAH and in stable subjects with
alcoholic cirrhosis to 1) characterize alterations in metabolic pathways associated
with acute AAH, and 2) identify potential metabolic biomarkers for disease
severity and prognosis.
Materials and Methods
Study Population
This prospective, case-control study was approved by the Institutional Review
Board (IRB) at the University of Pittsburgh in 2010. Twenty-five adults
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hospitalized with severe AAH (i.e., mDF .32) were recruited at the University of
Pittsburgh Medical Center in Pittsburgh, Pennsylvania from October 2010 to
December 2012. Inclusion criteria included: total bilirubin level of >3 mg/dL,
aspartate aminotransferase (AST): alanine aminotransferase (ALT) activity .2
with both levels ,500 U/L, and the presence of either hepatomegaly or steatosis
by ultrasound or computed tomography (CT) imaging in an individual with
heavy, chronic ethanol use. Patients were excluded if other chronic liver diseases,
including alpha-one antitrypsin deficiency, autoimmune hepatitis, hereditary
hemochromatosis, Wilson’s disease, drug-induced liver injury, primary biliary
cirrhosis, primary sclerosing cholangitis or Budd-Chiari Syndrome were present.
Patients with chronic viral hepatitis, however, were included. Individuals who last
consumed ethanol more than 6 weeks prior to clinical presentation were excluded.
Informed consent was obtained from either the subject or an authorized
representative prior to participation. The clinical diagnosis of AAH was confirmed
by two attending hepatologists (JB, SM) experienced in the treatment of alcoholic
hepatitis.
As most patients with AAH exhibit histologic evidence of micronodular
cirrhosis [13, 14], a control group of 25 clinically stable subjects with alcoholic
cirrhosis was derived from the IRB-approved University of Pittsburgh Center for
Liver Diseases Research Registry. All registry participants previously consented to
inclusion in the registry and provided serum samples for research use. All patient
records were reviewed to confirm the absence of acute alcoholic hepatitis.
Clinical and Demographic Information
Clinical and demographic data (Table 1) were obtained at the time of enrollment.
In patients with severe AAH, Maddrey’s discriminant function (mDF) was
calculated using the following formula [4]:
MDF5[PT (sec) – control PT (sec)]64.6+total bilirubin (mg/dl)
The laboratory control PT is 12.5 seconds at our institution. The Model for End
Stage Liver Disease (MELD) score was determined from the following equation
[15]:
MELD5(0.9576log [creatinine (mg/dl)]+0.3786log [total bilirubin (mg/
dl)]+1.1206log (INR)+0.643)610
Patients who underwent two or more dialysis treatments with one week of
enrollment were assigned a creatinine value of 4.0 mg/dl when calculating MELD.
Survival was determined using the Social Security Death Index.
Metabolomics Analysis
Venous blood samples were collected from hospitalized patients with severe AAH
within 24 hours of admission. Serum was obtained by centrifugation and stored at
280 C˚ until testing. Global, unbiased metabolic profiling was performed as
previously described [16].
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Data Acquisition and Statistical Analysis
Samples were analyzed over a two day period. Missing values for a given
metabolite were replaced with the observed minimum detection value for that
metabolite, based on the assumption that missing values were below the detection
limit. Raw data counts for each sample were then normalized to the median value
for each biochemical of interest.
Statistical analysis was performed using R (http://cran.r-project.org) and Stata
version 11 (StataCorp, College Station, TX). Welch’s t tests were carried out on
log-transformed data to compare relative biochemical concentrations between
experimental groups. False discovery rate (FDR) was estimated using q values to
account for multiple comparisons.
Random forest (RF) analysis was performed on untransformed data as
previously described to differentiate severe AAH and alcoholic cirrhosis cohorts
[17]. Principal component analysis was utilized to determine variation between
Table 1. Clinical and Demographic Characteristics of Patients.
Characteristics AAH (N525) Cirrhosis (N525) P
Age, yrs 50 (45–56) 55 (46–57) NS
Male, n (%) 17 (68%) 18 (72%) NS
Ethnicity, n (%)
Caucasian 23 (92%) 24 (96%) NS
Black 2 (8%) 1 (4%) NS
Other Liver Disease, n (%) 1 (4%) 11 (44%) 0.008
Hepatitis C 1 (4%) 10 (40%) ,0.001
Hepatitis B 0 (0%) 1 (4%) NS
Other 0 (0%) 0 (0%) NS
BMI, kg/m2 26.2 (23.4–33.0) 27.6 (25.3–30.1) NS
Diabetes, n (%) 2 (8%) 3 (12%) NS
Discriminant Function 52.5 (38.2–68.8) N/A N/A
MELD 26 (24–32) 11 (9–14) ,0.001
Albumin, g/L 2.0 (1.7–2.5) 3.2 (2.9–4.1) ,0.001
Bilirubin, mg/dl 15.0 (10.9–19.3) 1.3 (1.0–2.1) ,0.001
AST, IU/L 145 (100–235) 26 (20–51) ,0.001
ALT, IU/L 46 (38–64) 43 (32–63) NS
INR 2.0 (1.8–2.5) 1.3 (1.2–1.5) ,0.001
Creatinine, mg/dl 1.0 (0.8–2.0) 0.8 (0.8–1.1) NS
WBC count, x103/ml 10.9 (7.5–14.5) 5.6 (4.2–6.8) ,0.001
Hemoglobin, g/dl 10.6 (10.0–11.8) 13.6 (12.7–14.9) ,0.001
Platelet count, x 103/ml 127 (83–182) 89 (67–140) NS
30-day survival, n (%) 18 (72%) 25 (100%) ,0.001
90-day survival, n (%) 16 (64%) 25 (100%) ,0.001
180 day survival, n (%) 14 (56%) 25 (100%) ,0.001
Baseline characteristics of patients. All values are expressed as medians and IQRs unless otherwise specified. Continuous variables were compared with
Mann-Whitney U test. Categorical variables were compared with Fisher’s exact test. N/A: not applicable; NS: not signifnicant (p.0.05).
doi:10.1371/journal.pone.0113860.t001
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experimental groups [18], and integrated hierarchical clustering analysis was used
to classify patient cohorts by groupings of metabolites [19]. To determine global
patterns of metabolic pathway alterations, mass spectroscopic data were mapped
in a targeted manner using the Metscape application within the Cytoscape
platform [20, 21].
Demographic and clinical variables were presented as absolute frequencies,
percentages, medians and interquartile ranges. The x2 test was used to compare
categorical variables between groups (or Fischer’s exact test when expected values
were #5), and the Mann Whitney U test was used for continuous variables. A
two-tailed p value#0.05 was considered statistically significant.
Results
Patient characteristics
Demographic and clinical features of the study population are presented in
Table 1. Twenty-five patients were included in each cohort. Age, gender, and
ethnicity were similar between groups. The prevalence of diabetes was similar, and
both populations were overweight by mean BMI. More patients with alcoholic
cirrhosis had viral hepatitis, but subjects with AAH exhibited increased MELD
scores, AST levels and WBC counts with decreased hemoglobin and albumin.
While all cirrhotic patients were alive after 6 months, only 56% of AAH patients
survived beyond 180 days.
Metabolomics Analysis: Overview and Classification of Patient
Cohorts
A total of 420 distinct, named metabolites were identified in the serum samples.
Changes in metabolite concentrations between cohorts were determined using the
ratio of their group means, and these are displayed in Table S1. Overall, 234
statistically significant biochemical changes spanning multiple metabolic pathways
were observed; 152 molecules were significantly increased in patients with severe
AAH, while 82 were decreased. In addition, 17 biochemicals exhibited trends
toward significant difference between groups (0.05,p,0.10).
Using RF analysis, we determined that the metabolomics data set classified
samples into their respective groups with 100% accuracy. To assess the relative
contribution of each variable, the mean decrease accuracy (MDA) metric was used
[17, 22]. The 30 most important metabolites for the classification scheme are
depicted in Figure 1. Next, principal component analysis (PCA) was carried out
to show that the two groups were distinguishable by their metabolic signatures (
Figure 2). Finally, unbiased integrated hierarchical clustering analysis demon-
strated that differences in measured metabolites were grouped by subject cohorts
(Figure S1). Together, PCA, RF analysis, and integrated hierarchical clustering
methods demonstrate that AAH is characterized by distinct a metabolic profile.
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Targeted mapping of small molecules onto biochemical networks was
performed to determine global patterns of metabolic alterations in AAH.
Metabolic perturbations spanned multiple domains, including energy homeostasis
pathways, bile acid handling, bacterial metabolism, nucleic acid turnover,
antioxidant systems, and others (Figure 3).
Lipid metabolism in severe AAH is characterized by enhanced
adipose tissue lipolysis and altered fatty acid oxidation
Pathways related to lipid metabolism were significantly altered in severe AAH
compared to alcoholic cirrhosis, and several biochemicals associated with lipid
metabolism were identified in the RF analysis.
Figure 1. Random forest analysis of the thirty most important metabolites distinguishing patients with severe acute AAH from stable, alcoholic
cirrhotic controls.
doi:10.1371/journal.pone.0113860.g001
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Elevations in several long chain free fatty acids (LCFAs), and in particular two
essential fatty acids (eicosopentaenoate EPA; 20:5n3, docosapentaenoate n3 DPA;
22:5n6) were observed in patients with severe AAH (Figure S2A). This was
accompanied by decreased monoacylglycerols with increased glycerol levels
(Figure S2B). Overall these findings suggest that severe AAH is characterized by
enhanced lipolysis (Figure 4A), and adipose tissue lipolysis may increase
intrahepatic fatty acid influx in severe AAH. Potential etiologies for lipolysis
upregulation include peripheral insulin resistance, enhanced sympathetic tone, or
elevated stress hormone activity.
Beta oxidation is a primary fatty acid utilization pathway in the liver, and
dysregulation of fatty acid beta oxidation has been described in both alcoholic and
nonalcoholic liver disease [11, 23]. Beta oxidation primarily occurs in
mitochondria; while short- (SCFA) and medium chain fatty acids (MCFA) can
freely cross mitochondrial membranes, LCFA require carnitine shuttle systems to
enter mitochondria. In patients with severe AAH, increased lipolysis was
accompanied by metabolic changes suggestive of altered fatty acid beta oxidation.
In the AAH cohort, significantly reduced levels of the SCFA valerate and also
several MCFA were observed in conjunction with elevated acetylcarnitine and
Figure 2. Principal component analysis (PCA) of metabolomics data reveals clustering of data into separate cohorts. Control: alcoholic cirrhosis;
hepatitis: severe AAH.
doi:10.1371/journal.pone.0113860.g002
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ketones (Figure S3A, C), indicating ongoing mitochondrial beta-oxidation. At the
same time, multiple LCFA moieties and acylcarnitines were also elevated in the
severe AAH cohort (Figure S3B), implying either 1) incomplete LCFA beta
oxidation due to insufficient mitochondrial oxidative capacity that is over-
whelmed by FA flux from adipose tissue or 2) defective carnitine shuttle activity (
Figure 4B).
Omega oxidation is a minor pathway of fatty acid metabolism that occurs in
peroxisomes and is primarily responsible for processing very long chain fatty acids
(VLCFAs) into dicarboxylic acids. Omega oxidation is upregulated when beta
Figure 3. Global network analysis of relative measured metabolites in patients with alcoholic cirrhosis and severe AAH. Red nodes depict
metabolites that are increased in severe AAH when compared to alcoholic cirrhosis; yellow nodes depict metabolites that are decreased in severe AAH
when compared to alcoholic cirrhosis.
doi:10.1371/journal.pone.0113860.g003
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oxidation pathways are insufficient for a given FA load [24]. In patients with
severe AAH, serum levels of six dicarboxylic acids were significantly increased
(Figure S4, Figure 5A), and three of these (tetradecanedioate, hexadecanedioate,
octadecanedioate) were also identified in the RF analysis as important
contributors for identification of severe AAH patients. These changes reflect
enhanced omega oxidation in severe AAH and support the notion of inadequate
beta-oxidative capacity for a FA disposal. Furthermore, dicarboxylic acids are
known peroxisome proliferator-activated receptor a (PPARa) ligands and may
regulate intrahepatic lipid partitioning in AAH [25].
Deceased phospholipid and lysolipid turnover may reflect
changes in plasma membrane remodeling in severe AAH
Phospholipids and lysolipids are the principal components of lipid bilayers in cell
membranes. Phospholipids are composed of a diacylglycerol group, phosphate
Figure 4. Schematic representations of altered triglyceride hydrolysis and mitochondrial fatty acid
beta-oxidation in severe AAH. (A) Triglyceride hydrolysis. (B). Mitochondrial fatty acid beta-oxidation.
doi:10.1371/journal.pone.0113860.g004
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head group and an organic molecule, while lysolipids resemble phospholipids
except for the replacement of diacylglycerol with monoacylglycerol.
Phospho(lyso)lipid degradation and synthesis contribute to plasma membrane
remodeling. Compared to cirrhotic patients, subjects with severe AAH exhibited
significant reductions in three major phospholipid metabolites – choline,
glycerophosphocholine (GPC) and glycerol-3-phosphate. Furthermore, the
majority of detected lysolipids were decreased (Figure 5B, Figure S5). Two
lysolipids – 1-linoleoylglycerophosphoethanolamine (1-linoleoyl-GPE) and 2-
linoleoylglycerophosphoethanolamine (2-linoleoyl-GPE) – along with GPC were
identified in the RF analysis as key metabolites for identification of severe AAH.
Finally, increased levels of other important membrane components including
cholesterol and sphingosine were observed (Table S1). Together, these findings
may reflect significant reductions in cell membrane remodeling in patients with
AAH.
Figure 5. Schematic representations of altered fatty acid omega-oxidation and lysolipid and
phospholipid turnover in severe AAH. (A) Fatty acid omega-oxidation. (B) Lysolipid and phospholipid
turnover.
doi:10.1371/journal.pone.0113860.g005
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Alterations in bile acid composition and xenobiotic metabolism
may indicate intestinal dysbiosis in severe AAH
Cholestasis with associated elevation of serum bile acids is commonly
encountered in alcoholic hepatitis, and accordingly, several secondary bile acids
were increased in this cohort (Figure 6A,D). Sulfation is a key mechanism for
increasing bile acid solubility for urinary excretion, and levels of three detected
sulfated bile acid were elevated as well (Figure 6B). Both taurocholenate sulfate
and deoxycholate were identified in the RF analysis, thus highlighting the
importance of cholestasis as a key metabolic feature of severe AAH.
Conversely, the bile acids deoxycholate and glycodeoxycholate, were decreased (
Figure 6C); as these bile acids are derived from intestinal bacterial metabolism,
this may suggest altered gut microbial composition in severe AAH. Furthermore,
several products of benzoate degradation were significantly reduced in patients
with severe AAH, and this finding was corroborated by evidence of altered gut
microbial benzoate metabolism (Figure 7, Figure 3). Together, these findings
provide evidence of intestinal dysbiosis in patients with severe AAH.
Severe AAH is characterized by changes in glucose utilization
and tricarboxylic acid (TCA) cycle activity
In the absence of hepatic dysfunction or fasting, glucose is preferentially
consumed to generate adenosine triphosphate (ATP) through glycolysis, the TCA
cycle, and oxidative phosphorylation. In severe AAH, reduced glucose utilization
was observed. Despite increased levels of serum lactate, elevations in glucose,
fructose, and several sugar alcohols suggest glucose shunting away from glycolysis
and towards the pentose phosphate pathway (PPP) (Figure S6A,B). In this
context, increased lactate levels may reflect impaired hepatic or renal clearance.
Furthermore, the PPP end product xylonate was identified in the RF analysis as a
key marker of severe AAH. As the PPP is critical for generation of NADPH to
neutralize reactive oxygen intermediates, elevations in PPP metabolites likely
reflect increased oxidative stress in patients with AAH (Figure 8A).
Severe AAH was associated with a 15-fold increase in glucuronate. Additionally,
glucuronate was identified as the most important molecule for AAH discrimi-
nation by RF analysis. As an important glucose derivative, glucuronate is
conjugated to xenobiotics, bile acids, and bilirubin via UDP-glucuronosyl
transferases (UGTs) to increase solubility and excretion. In particular,
glucuronidation is essential for the elimination of bilirubin. In the AAH cohort,
the median bilirubin level was significantly elevated at 15.0 mg/dl, suggesting that
elevated glucuronate levels were related to either impaired or overwhelmed
hepatic UGT capacity (Figure 8A).
Multiple intermediates of the TCA cycle, including malate, fumarate, succinate
(in the form of succinylcarnitine) and citrate were increased in patients with
severe AAH compared to cirrhotic controls (Figure 8B, Figure S6D); these
findings are consistent with altered mitochondrial ATP production. Several
potential TCA cycle substrates have been identified in this analysis, including
Serum Metabolomic Profiling in Severe Acute Alcoholic Hepatitis
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products of FA metabolism and protein catabolism. For example, as there is
evidence of ongoing FA beta-oxidation in severe AAH, acetylcarnitine end-
products may drive Krebs cycle activity through increased acetyl-CoA availability.
On the other hand, reduced glucose utilization via glycolysis may decrease
pyruvate availability for conversion to acetyl-CoA.
Changes in AA metabolite and peptide derivatives suggest
increased protein catabolism for energy production
Amino acids provide yet another substrate for energy production, and marked
changes in protein metabolism were noted in patients with severe AAH. In
particular, significant reductions in all three branched-chain amino acids
(BCAAs) were accompanied by increased levels of BCAA metabolites (Figure S7A,
B). In addition, levels of TCA cycle intermediates derived from BCAA were
increased in patients with severe AAH. As skeletal muscle is the primary site of
BCAA catabolism, these findings suggest increased utilization of BCAA by skeletal
muscle as an energy substrate.
Figure 6. Alterations in serum bile acid levels in patients with severe acute alcoholic hepatitis (hepatitis) and stable alcoholic cirrhosis (control).
(A) Secondary bile acids. (B) Sulfated bile acids. (C) Products of gut microbial bile acid metabolism. (D) Schematic representation of altered bile acid
turnover in severe AAH. * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0113860.g006
Figure 7. Alterations in serum levels of metabolites derived from intestinal microbial benzoate metabolism in patients with severe acute alcoholic
hepatitis (hepatitis) and stable alcoholic cirrhosis (control). * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0113860.g007
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Post-translational modification of amino acids occurs in the liver to enhance
AA excretion, and levels of several modified amino acids (by glycosylation,
acetylation, and formylation), were enhanced in the severe AAH cohort (Table 2).
Of note, N-acetyltryptophan levels were increased 421-fold in severe AAH
compared to cirrhotic controls, and N-acetyl-serine was identified in the RF
analysis as a key component of the metabolic signature of AAH. There was a trend
Figure 8. Schematic representations of altered serum metabolites involved in glucose utilization and TCA cycle activity in severe AAH. (A)
Glucose utilization pathways. (B) TCA cycle.
doi:10.1371/journal.pone.0113860.g008
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towards increased urea levels with decreased arginine and citrulline levels in severe
AAH (Figure S7C), reflecting increased hepatic disposal of nitrogenous
compounds, including amino acids. Finally, several dipeptides (phenylalanyl-
tryptophan, leucylalanine, prolylhydroxyproline, phenylalanylphenylalanine, and
phenylalanylleucine) were detected in the RF analysis discriminating severe AAH
from alcoholic cirrhosis (Figure 1, Table 2). Together, these findings highlight
the importance of increased protein degradation and amino acid catabolism for
maintaining energy homeostasis in severe AAH.
Metabolic alterations in severe AAH indicate an oxidative
environment and increased inflammation
Altered levels of several biomolecules highlighted the contributions of oxidative
stress, antioxidant depletion and inflammation to metabolic phenotypes in severe
AAH. In addition to enhanced levels of pentose phosphate pathway metabolites,
serum symmetric dimethylarginine (SDMA), an important regulator of monocyte
endothelial ROI generation [26] was significantly increased in patients with severe
AAH versus cirrhotic controls. As SDMA undergoes renal excretion, serum levels
may reflect subclinical renal dysfunction in this cohort. Other oxidized
Table 2. Serum levels of protein degradation products.
Metabolite Fold Change (AAH vs. Cirrhosis) P Value Q Value
N-acetylglycine 1.74 ,0.001 ,0.001
N-acetylserine 2.66 ,0.001 ,0.001
N-acetylthreonine 1.99 0.0038 0.0033
N-acetyl-beta-alanine 1.49 ,0.001 ,0.001
N-acetylalanine 1.78 ,0.001 ,0.001
N6-acetyllysine 1.44 ,0.001 ,0.001
N-acetylphenylalanine 1.72 0.0033 0.0029
N-acetyltryptophan 421.50 0.0102 0.0072
N-acetylmethionine 1.62 0.0035 0.003
Aspartylphenylalanine 0.48 ,0.001 ,0.001
Prolylalanine 1.51 0.0036 0.0031
Leucyleucine 0.64 0.0166 0.0105
Pro-hydroxyproline 2.57 ,0.001 ,0.001
Phenylalanylphenylalanine 0.25 ,0.001 ,0.001
Valylarginine 0.43 ,0.001 ,0.001
Histidyltryptophan 0.40 ,0.001 ,0.001
Leucylalanine 0.31 ,0.001 ,0.001
Phenylalanylleucine 0.31 ,0.001 ,0.001
Phenylalanylserine 0.54 ,0.001 ,0.001
Phenylalanyltyptophan 0.24 ,0.001 ,0.001
Relative levels of serum protein degradation products, including acetylated amino acids, dipeptides, and urea cycle intermediates. Serum levels of each
metabolite were compared using paired Welch’s t tests, and q values were calculated to account for false discovery rates to correct for multiple comparisons.
doi:10.1371/journal.pone.0113860.t002
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metabolites, including biliverdin and erythronate were also greater in AAH
(Figure S8). Furthermore, three of six detected monohydroxylated fatty acids
were increased, as was 1,2-propanediol, a metabolite derived from methylglyoxal
detoxification [27]. Together, these findings reflect enhanced oxidative stress in
severe AAH.
Conversely, the metabolomics analysis revealed evidence of altered antioxidant
utilization in severe AAH. Glutathione is a key antioxidant synthesized both from
de novo and salvage pathways within in the liver. In patients with severe AAH,
levels of both alpha-ketobutyrate and alpha-hydroxybutyrate were significantly
increased, suggesting shunting of homocysteine to glutathione synthesis.
Interestingly, this was accompanied by increased methionine levels, which may
reflect decreased utilization of methionine for S-adenosyl methionine (SAMe)
generation. Finally, there was a trend towards higher levels of 5-oxoproline
Figure 9. Alterations in inflammation-associated metabolites in AAH. (A) Serum levels of tryptophan metabolites in patients with severe acute alcoholic
hepatitis (hepatitis) and stable alcoholic cirrhosis (control). (B) Schematic representation of altered indoleamine 2,3-dioxygenase activity in severe AAH. (C)
Serum levels of lipid-derived inflammatory mediators in patients with severe acute alcoholic hepatitis (hepatitis) and stable alcoholic cirrhosis (control). *
p,0.05, ** p,0.01, *** p,0.001. IDO, indoleamine 2,3-dioxygenase; TNF-a, tumor necrosis factor a; IFN-c, interferon-c.
doi:10.1371/journal.pone.0113860.g009
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(p50.066), a marker of glutathione degradation. In addition, significant
reductions in ascorbate (vitamin C) and gamma-CEHC (a product of gamma-
tocopherol metabolism) were observed, indicating either antioxidant depletion or
malnutrition (Figure S8).
In conjunction with increased oxidative stress and decreased antioxidant
capacity, altered levels of several biochemicals highlighted the profound
inflammation seen in acute AAH. Indoleamine 2,3-dioxygenase (IDO) is a highly-
inducible enzyme which is up-regulated by the inflammatory cytokines tumor
necrosis factor a (TNFa) and interferon-gamma (IFN-c) [28, 29]. Tryptophan
was preferentially shunted towards IDO metabolism and away from serotonin
synthesis, as the IDO product kynenurate was increased while serotonin levels
were decreased in patients with severe AAH (Figure 9A,B). Together, these
findings reflect increased TNF-a and IFN-c-mediated inflammation. In addition,
serum levels of cortisol as well as the proinflammatory molecules 12-HETE and
palmitoyl ethanolamide were significantly higher in patients with severe AAH (
Figure 9C). In total, these markers of oxidative stress and inflammation confirm
known associations between these pathways and the pathogenesis of AAH.
Table 3. Serum levels of significantly altered metabolites between AAH survivors and nonsurvivors.
Pathway Metabolite Fold Change* P Q
Glutamate Metabolism glutamine 0.72 0.0285 0.4415
Aromatic AA Metabolism 3-methoxytyrosine 1.39 0.042 0.4415
BCAA Metabolism 3-hydroxyisobutyrate 1.72 0.046 0.4415
SH-Containing AA Metabolism a-ketobutyrate 2.76 0.044 0.4415
2-hydroxybutyrate 1.82 0.04523 0.4415
S-methylcysteine 0.75 0.0226 0.4415
Dipeptide Metabolism valylarginine 0.45 0.0215 0.4415
Glucose Metabolism glucose 1.22 0.0454 0.4415
Pentose Phosphate Pathway threitol 2.04 0.0499 0.4415
Mannose Metabolism mannose 1.46 0.0358 0.4415
Branched FA Metabolism 17-methylstearate 1.49 0.0398 0.4415
Acyl Carnitine Metabolism hexanoylcarinitine 1.72 0.0433 0.4415
decanoylcarnitine 1.60 0.0336 0.4415
Lysolipid Metabolism 1-linoleoylglycerophosphoethanolamine 0.39 0.0182 0.4415
Sterol Metabolism b-sitosterol 1.79 0.0430 0.4415
Steroid Metabolism 21-hydroxypregnenolone disulfate 2.83 0.0049 0.4415
pregn-steroid monosulfate 2.88 0.0309 0.4415
4-androsten-3-beta,17-betadiol disulfate 1.89 0.0427 0.4415
Purine Metabolism N1-methyladenosine 1.20 0.0429 0.4415
Porphyrin Metabolism heme 1.88 0.0280 0.4415
Relative levels of serum metabolites between survivors and nonsurvivors with severe AAH. Serum levels of each metabolite were compared using paired
Welch’s t tests, and q values were calculated to account for false discovery rates to correct for multiple comparisons. AA, amino acid; BCAA, branched-chain
amino acid; FA, fatty acid. *Fold change Survivor vs. Non-survivor.
doi:10.1371/journal.pone.0113860.t003
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A panel of metabolic biomarkers identify long-term survivors with
severe AAH
As only 56% of patients with severe AAH survived to 180 days, we sought to
identify metabolic biomarkers associated with mortality. Treatments likely did not
explain differences in survival of patients with severe AAH, as similar proportions
of survivors and non-survivors received prednisolone (31.4% of survivors versus
42.6% of non- survivors, p5N.S.), pentoxifylline (64.5% versus 70.9%, p5N.S.),
both medications (5.7% versus 11.6%, p5N.S.) or neither medication. (4.7%
versus 9.8%, p5N.S.). Overall, levels of twenty named metabolites were
significantly different between survivors and non- survivors with severe AAH
(Table 3). Of these, four biochemicals were elevated in survivors, while 16 were
decreased. Multiple metabolites that were altered between severe AAH and
alcoholic cirrhosis also differed between survivors and nonsurvivors. In particular,
the biomolecule 3-hydroxybutyrate, which was identified in the RF analysis
distinguishing severe AAH from alcoholic cirrhosis, was also elevated in survivors
of severe AAH.
Next, we performed univariable exact logistic regression analysis to determine
predictors of 6-month survival in severe AAH. Of the twenty biomarkers studied,
15 were significantly associated with mortality in this cohort (Table 4).
Table 4. Metabolic predictors of 180-day survival in severe AAH by logistic regression analysis.
Metabolite Univariate O.R. 95% C.I. P
glutamine 23.994 1.215–1192.400 0.034
3-methoxytyrosine 0.084 0.005–0.825 0.032
3-hydroxyisobutyrate 0.400 0.114–0.987 0.045
a-ketobutyrate 0.339 0.095–0.862 0.018
2-hydroxybutyrate 0.510 0.229–0.968 0.038
S-methylcysteine 31.712 1.334–2131.335 0.028
valylarginine 30.848 1.705–1669.992 0.013
glucose 0.917 0.485–1.718 0.778
threitol 0.743 0.453–1.067 0.124
mannose 0.128 0.013–0.746 0.018
17-methylstearate 0.196 0.028–0.918 0.037
hexanoylcarinitine 0.530 0.218–1.037 0.066
decanoylcarnitine 0.297 0.047–1.006 0.052
1-linoleoylglycerophosphoethanolamine 15.767 1.129–737. 559 0.033
b-sitosterol 0.228 0.285–0.987 0.047
21-hydroxypregnenolone disulfate 0.206 0.028–0.802 0.009
pregn-steroid monosulfate 0.262 0.039–0.900 0.025
4-androsten-3-beta,17-betadiol disulfate 0.706 0.459–0.993 0.045
N1-methyladenosine 0.035 0.001–0.985 0.049
heme 0.680 0.349–1.148 0.174
Univariable logistic regression analysis for metabolic predictors of 180-day survival in severe AAH. AA, amino acid; BCAA, branched-chain amino acid; FA,
fatty acid; O.R., odds ratio; C.I., confidence interval.
doi:10.1371/journal.pone.0113860.t004
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Discussion
In this prospective case control study, we utilized unbiased serum metabolomics
to characterize alterations in pathways associated with severe AAH. Three
important observations were noted. First, we demonstrated that changes in serum
metabolites accurately discriminated AAH from alcoholic cirrhosis. Next, we
described differences in biochemical levels related to several metabolic pathways,
including lipid metabolism, bile acid homeostasis, protein utilization, glucose
disposal, oxidative stress, and inflammation. Finally, we identified a panel of
metabolic biomarkers that differed between survivors and nonsurvivors with
severe AAH for future analysis.
Random forest (RF) classification of serum metabolic profiles distinguished
severe AAH from alcoholic cirrhosis with 100% accuracy, thus indicating that
differences between the two groups were quite pronounced. RF analysis was also
used to identify the 30 most important biochemicals separating severe AAH from
alcoholic cirrhosis, and principal component analysis (PCA) demonstrated that
metabolic signatures of severe AAH varied greatly from those related to alcoholic
cirrhosis. Together, RF analysis and PCA provide compelling evidence that severe
AAH is characterized by a distinct metabolic phenotype spanning several
metabolic pathways.
Animal models of alcoholic liver disease have demonstrated dysfunctional
adipose and hepatic lipid metabolism, including adipose tissue hyperlipolysis,
defective hepatic lipid catabolism, and altered lipid trafficking [7–9, 12, 30].
Similar to these findings, patients with severe AAH in the current study exhibited
enhanced adipose tissue triglyceride lipolysis, relative impairment of hepatic fatty
acid beta oxidation, and enhanced fatty acid omega oxidation. In particular,
accumulation of incomplete LCFA degradation products suggests reduced
mitochondrial oxidative capacity for a large FA load. In addition to enhanced
adipose tissue lipolysis and dysfunctional fatty acid oxidation, changes in other
lipid-derived metabolites were also observed. Low serum levels of multiple
phospholipids, lysolipids, and associated degradation products suggest decreased
cell membrane remodeling in severe AAH [31, 32].
While levels of most serum bile acids were elevated in patients with severe AAH,
levels of two gut microbiota-derived moieties, deoxycholate and glycodeoxycho-
late, were decreased. Additionally, pronounced changes in enteric microbial
benzoate handling were identified in patients with severe AAH. Similar
phenomena have been described in metabolomics studies of intestinal microbial
alteration in inflammatory conditions such as obesity and inflammatory bowel
disease. Together, these findings highlight a role for intestinal dysbiosis in severe
AAH [33–35].
Metabolomics profiling also highlighted several changes in substrate utilization
for energy homeostasis. The accumulation of several sugar alcohols in patients
with severe AAH indicated glucose shunting towards the pentose phosphate
pathway, an important source of reduced nicotinamide adenine dinucleotide
(NADH) to neutralize oxidative stress. Observed elevations in serum lactate levels
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may be related to impaired hepatic clearance, as previous human and animal
studies have demonstrated decreased gluconeogenesis in the setting of alcohol
consumption [36]. Increased levels of multiple TCA cycle intermediates in
patients with severe AAH reflect decreased mitochondrial energy metabolism, and
high levels of multiple protein degradation products pointed to increased
utilization of amino acids as a primary energy substrate in this population.
The metabolic phenotype of AAH is characterized by oxidative stress resulting
in systemic inflammation [37, 38], and to this effect levels of several oxidized
metabolites were elevated in severe AAH. Pronounced depletion of antioxidants,
including vitamin C and the vitamin A metabolite gamma-CEHC was observed,
and multiple metabolites related to glutathione turnover were altered. These
changes were associated with increased kynenurate, decreased serotonin, and
decreased tryptophan levels, likely mediated by the highly-inducible enzyme IDO.
As IDO expression is up-regulated by TNFa and IFN-c [28, 29], these findings
underscore the role of systemic inflammation in severe AAH.
Finally, we compared metabolite levels in survivors and non-survivors with
severe AAH to determine potential biomarkers of disease severity and prognosis.
Twenty metabolites spanning multiple metabolic pathways were significantly
different between groups, and of these biomarkers, 15 were significantly associated
with 6-month survival by univariable logistic regression analysis. This difference
was not related to treatment effects, as exposure to corticosteroids and
pentoxifylline was similar between survivors and non-survivors. Together, these
metabolites represent a potential biomarker panel for disease prognosis and may
shed light on the pathogenesis of severe AAH.
A few limitations were noted. First, the serum metabolome represents the net
result of metabolic changes in several tissues; nonetheless, many of the
biomolecules identified in the current study were primarily derived from energy
homeostasis organs, including the liver, adipose tissue, and skeletal muscle.
Second, quantification of ethanol consumption was not obtained from most
patients, and many of the metabolic pathways studied are directly regulated by
ethanol. Even so, levels of ethyl glucuronide, a derivative of ethanol metabolism
commonly used to assess long-term abstinence [39, 40], were similar between
patients with severe AAH and alcoholic cirrhosis, and all patients with severe AAH
underwent blood collection within 24 hours of admission. Finally, small sample
sizes (n525 per group) may have increased the probability of type II error in
hypothesis testing. Despite the sample size, however, a distinct metabolic
phenotype for severe AAH was defined.
In conclusion, our findings define the rich metabolic signature of severe AAH
and identify potential metabolic biomarkers of disease prognosis. Future studies
are planned to validate these findings in larger cohorts of patients with severe
AAH.
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Supporting Information Legends
Figure S1. Unbiased hierarchical clustering analysis of measured metabolites
between subject cohorts.
doi:10.1371/journal.pone.0113860.s001 (TIF)
Figure S2. Serum levels of long chain free fatty acids (LCFA) and triglyceride
hydrolysis intermediates in patients with severe acute alcoholic hepatitis
(hepatitis) and stable alcoholic cirrhosis (control). (A) Long chain free fatty
acids. (B) Triglyceride hydrolysis intermediates. * p,0.05, ** p,0.01, ***
p,0.001.
doi:10.1371/journal.pone.0113860.s002 (TIF)
Figure S3. Serum levels of short-(SCFA) and medium-chain fatty acids
(MCFA), fatty acylcarnitines, and ketone bodies in patients with severe acute
alcoholic hepatitis (hepatitis) and stable alcoholic cirrhosis (control). (A)
Short- and medium-chain fatty acids. (B) Fatty acylcarnitines. (C) Ketone bodies.
* p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0113860.s003 (TIF)
Figure S4. Serum levels of dicarboxylic acids in patients with severe acute
alcoholic hepatitis (hepatitis) and stable alcoholic cirrhosis (control). p,0.05,
** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0113860.s004 (TIF)
Figure S5. Serum levels of lysolipids and intermediates of lysolipid and
phospholipid metabolism in patients with severe acute alcoholic hepatitis
(hepatitis) and stable alcoholic cirrhosis (control). (A) Lysolipids. (B)
Intermediates of lysolipid and phospholipid metabolism. * p,0.05, ** p,0.01, ***
p,0.001.
doi:10.1371/journal.pone.0113860.s005 (TIF)
Figure S6. Serum levels of glucose utilization pathway and tricarboxylic acid
(TCA) cycle intermediates in patients with severe acute alcoholic hepatitis
(hepatitis) and stable alcoholic cirrhosis (control). (A) Glucose with associated
metabolic products. (B) Pentose phosphate pathway intermediates. (C)
Glucuronate and 2,3-butanediol. (D) Tricarboxylic acid (TCA) cycle intermedi-
ates. * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0113860.s006 (TIF)
Figure S7. Serum levels of branched-chain amino acids (BCAA), BCAA
degradation products, and urea cycle intermediates in patients with severe
acute alcoholic hepatitis (hepatitis) and stable alcoholic cirrhosis (control). (A)
Branched-chain amino acids. (B) BCAA degradation products. (C) Urea cycle
intermediates. * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0113860.s007 (TIF)
Figure S8. Serum levels of oxidized biomolecules, monohydroxy fatty acids,
intermediates of glutathione metabolism and antioxidants in patients with
severe acute alcoholic hepatitis (hepatitis) and stable alcoholic cirrhosis
Serum Metabolomic Profiling in Severe Acute Alcoholic Hepatitis
PLOS ONE | DOI:10.1371/journal.pone.0113860 December 2, 2014 21 / 24
(control). (A) Oxidized biomolecules. (B) Monohydroxy fatty acids. (C)
Intermediates of glutathione metabolism. (D) Antioxidants. * p,0.05, ** p,0.01,
*** p,0.001.
doi:10.1371/journal.pone.0113860.s008 (TIF)
Table S1. Serum metabolite concentrations from patients with severe acute
alcoholic hepatitis (hepatitis) and stable alcoholic cirrhosis (control).
doi:10.1371/journal.pone.0113860.s009 (XLSX)
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